Imatinib mesylate in desmoplastic small round cell tumors

被引：12

作者：

De Sanctis, Rita ^{[1
,2
]}

Bertuzzi, Alexia ^{[1
,3
]}

Bisogno, Gianni ^{[4
]}

Carli, Modesto ^{[4
]}

Ferrari, Andrea ^{[5
]}

Comandone, Alessandro ^{[6
,7
]}

Santoro, Armando ^{[1
,8
]}

机构：

[1] IRCCS, Humanitas Canc Ctr, Dept Med Oncol & Hematol, Milan, Italy

[2] Sapienza Univ, Dept Anat Histol Forens Med & Orthopaed, Mol & Cellular Networks Lab, Rome, Italy

[3] Inc Natl Childrens Hosp AMNCH, Med Oncol Adelaide & Meath Hosp, Dublin, Ireland

[4] Univ Padua, Pediat Med Oncol & Hematol Unit, Padua, Italy

[5] Fdn IRCCS, Ist Nazl Tumori, Pediat Oncol Unit, Milan, Italy

[6] Gradenigo Hosp, Dept Oncol, Turin, Italy

[7] Grp Piemontese Sarcomi, Turin, Italy

[8] Humanitas Univ, Milan, Italy

来源：

FUTURE ONCOLOGY | 2017年 / 13卷 / 14期

关键词：

c-KIT; desmoplastic small round cell tumor; imatinib; PDGF-R alpha; PDGF-R beta; PHASE-II; SARCOMA; PRODUCT;

D O I：

10.2217/fon-2016-0305

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To investigate the possible role of imatinib, an inhibitor of the tyrosine kinase activity of PDGF-R, in desmoplastic small round cell tumor (DSRCT). Patients & methods: From August 2005 to June 2009, DSRCT patients refractory to conventional treatment were enrolled. Patients received imatinib 400 mg daily. Primary end point of this open label, prospective, Phase II trial was objective response rate. Results: Of the 13 enrolled patients, eight were evaluable for response. Median age was 20 years (range: 9-32). Objective responses at 3 months were: stable disease in one patient and progressive disease in seven patients. Conclusion: Imatinib showed no efficacy in the treatment of DSRCT unresponsive to conventional therapy, despite molecular-based selection of patients.

引用

页码：1233 / 1237

页数：5

共 13 条

[1]

Aguilera D, 2008, SARCOMA, V16, P257

[2] A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children's oncology group study [J].

Bond, Mason ;

Bernstein, Mark L. ;

Pappo, Alberto ;

Schultz, Kirk R. ;

Krailo, Mark ;

Blaney, Susan M. ;

Adamson, Peter C. .

PEDIATRIC BLOOD & CANCER, 2008, 50 (02) :254-258

[3]

Chao J, 2010, ANTICANCER RES, V30, P547

[4] Retroperitoneal desmoplastic small round cell tumor: Pediatric patient treated with multimodal therapy [J].

Kim, Yong Seok ;

Cha, Seong Jae ;

Choi, Yoo Shin ;

Kim, Beom Gyu ;

Park, Sung Jun ;

Chang, In Taik .

WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (33) :4212-4214

[5] Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein - A phase II clinical trial [J].

Krug, LM ;

Crapanzano, JP ;

Azzoli, CG ;

Miller, VA ;

Rizvi, N ;

Gomez, J ;

Kris, MG ;

Pizzo, B ;

Tyson, L ;

Dunne, M ;

Heelan, RT .

CANCER, 2005, 103 (10) :2128-2131

[6] The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour [J].

Lee, SB ;

Kolquist, KA ;

Nichols, K ;

Englert, C ;

Maheswaran, S ;

Ladanyi, M ;

Gerald, WL ;

Haber, DA .

NATURE GENETICS, 1997, 17 (03) :309-313

[7]

Merchant MS, 2002, J NATL CANCER I, V94, P1673

[8] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[9] Desmoplastic small round cell tumor in childhood: The St. Jude Children's Research Hospital experience [J].

Saab, Raya ;

Khoury, Joseph D. ;

Krasin, Matthew ;

Davidoff, Andrew M. ;

Navid, Fariba .

PEDIATRIC BLOOD & CANCER, 2007, 49 (03) :274-279

[10] Lack of clinical efficacy of imatinib in metastatic melanoma [J].

Ugurel, S ;

Hildenbrand, R ;

Zimpfer, A ;

La Rosée, P ;

Paschka, P ;

Sucker, A ;

Keikavoussi, P ;

Becker, JC ;

Rittgen, W ;

Hochhaus, A ;

Schadendorf, D .

BRITISH JOURNAL OF CANCER, 2005, 92 (08) :1398-1405

← 1 2 →